IMCR
NASDAQImmunocore Holdings plc
Website
News25/Ratings12
News · 26 weeks33-40%
2025-10-262026-04-19
Mix2190d
- Other8(38%)
- SEC Filings5(24%)
- Insider5(24%)
- Earnings2(10%)
- Analyst1(5%)
Latest news
25 items- PRKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, elevated LDH, and extrahepatic disease as well as those with best response of progressive disease This is the longest OS follow-up in a randomized trial in metastatic uveal melanoma and for any T cell engager in a solid tumor (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 19 April 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicin
- SECSEC Form DEF 14A filed by Immunocore Holdings plcDEF 14A - Immunocore Holdings plc (0001671927) (Filer)
- PRImmunocore to present at the 25th Annual Needham Virtual Healthcare ConferenceImmunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate in the 25th Annual Needham Virtual Healthcare Conference. 25th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 13, 2026, at 3:00 p.m. EDT The presentation will be webcast li
- PRImmunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meetingImmunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will present the five-year overall survival (OS) from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with unresected or metastatic uveal melano
- ANALYSTImmunocore downgraded by Jefferies with a new price targetJefferies downgraded Immunocore from Buy to Hold and set a new price target of $33.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plcSCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)
- PRNext-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor TypesIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 5, 2026 /CNW/ -- Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and immunotherapy[1]. Yet cancer remains the second-leading cause of death worldwide, with an estimated 2.1 million new diagnoses expected in 2026 alone and mortality rates still climbing among younger populations[2]. Companies delivering next-generation oncology treatments across multiple tumor types include Oncolytics Biotech (NASDAQ:ONCY), Vir Biotechnology (NASDAQ:VIR), Iovance Biotherapeutics (NASDAQ:IOVA), C4 Therapeutic
- PRImmunocore to present at upcoming investor conferencesImmunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 03 March 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in March. TD Cowen 46th Annual Healthcare Conference Presentation: Tuesday, March 3, 2026, at 2:30 p.m. EST Leerink 2026 Global Healthcare Conference Fireside Chat: Monday, March
- SECImmunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immunocore Holdings plc (0001671927) (Filer)
- SECSEC Form 10-K filed by Immunocore Holdings plc10-K - Immunocore Holdings plc (0001671927) (Filer)
- PRImmunocore reports fourth quarter and full year 2025 financial results and provides a business updateImmunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IMC-P115C) Additional Phase 1 HIV data to be presented in 2H 2026 Cash, cash equivalents and marketable securities of $864.2 million as of December 31, 2025 Conference call today, February 25 at 8:00AM ET
- INSIDERSEC Form 4 filed by Chief Financial Officer Coy Travis Alan4 - Immunocore Holdings plc (0001671927) (Issuer)
- INSIDERCHIEF HR OFFICER St Leger Tina Amber converted options into 2,119 units of Ordinary Shares and sold $32,350 worth of Ordinary Shares (1,000 units at $32.35) (SEC Form 4)4 - Immunocore Holdings plc (0001671927) (Issuer)
- INSIDERSVP, FINANCE & CAO Goll John converted options into 1,351 units of Ordinary Shares and sold $22,580 worth of Ordinary Shares (698 units at $32.35) (SEC Form 4)4 - Immunocore Holdings plc (0001671927) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Jallal Bahija converted options into 23,817 units of Ordinary Shares and sold $371,184 worth of Ordinary Shares (11,474 units at $32.35) (SEC Form 4)4 - Immunocore Holdings plc (0001671927) (Issuer)
- INSIDERHEAD OF R&D Berman David M sold $192,968 worth of Ordinary Shares (5,965 units at $32.35) and converted options into 11,824 units of Ordinary Shares (SEC Form 4)4 - Immunocore Holdings plc (0001671927) (Issuer)
- SECSEC Form 144 filed by Immunocore Holdings plc144 - Immunocore Holdings plc (0001671927) (Subject)
- PRImmunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Wednesday, February 25, 2026. Following the announcement, the Company will host a live teleconference and webcast a
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Immunocore Holdings plcSCHEDULE 13G/A - Immunocore Holdings plc (0001671927) (Subject)
- SECImmunocore Holdings plc filed SEC Form 8-K: Leadership Update8-K - Immunocore Holdings plc (0001671927) (Filer)
- PRImmunocore announces R&D leadership evolutionImmunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President roles (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 30 January 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that Dr. David Berman, Executive Vice President, Research and Development, will leave the Company effect
- SECImmunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Immunocore Holdings plc (0001671927) (Filer)
- PRImmunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare ConferenceImmunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma indications – TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp combinations in ovarian and lung cancer and initial data with half-life extended candidate (IMC-P115C) Additional Phase 1 HIV data to be presented in 2H 2026 Planning to dose first patient in Phase 1 type 1 diabetes trial in 1H
- ANALYSTImmunocore upgraded by UBS with a new price targetUBS upgraded Immunocore from Sell to Buy and set a new price target of $55.00
- INSIDERHEAD OF R&D Berman David M exercised 31,913 units of Ordinary Shares at a strike of $17.46 and sold $1,284,749 worth of Ordinary Shares (31,913 units at $40.26) (SEC Form 4)4 - Immunocore Holdings plc (0001671927) (Issuer)